Please use this identifier to cite or link to this item: http://repositorio.unicamp.br/jspui/handle/REPOSIP/356301
Full metadata record
DC FieldValueLanguage
dc.contributor.CRUESPUNIVERSIDADE ESTADUAL DE CAMPINASpt_BR
dc.contributor.authorunicampDe Nucci, Gilberto-
dc.typeArtigopt_BR
dc.titleA proof‐of‐concept, Phase 2 clinical trial of the gastrointestinal safety of a hydrogen sulfide‐releasing anti‐inflammatory drugpt_BR
dc.contributor.authorWallace, John L.-
dc.contributor.authorNagy, Peter-
dc.contributor.authorFeener, Troy D.-
dc.contributor.authorAllain, Thibault-
dc.contributor.authorDitrói, Tamás-
dc.contributor.authorVaughan, David J.-
dc.contributor.authorMuscara, Marcelo N.-
dc.contributor.authorNucci, Gilberto de-
dc.contributor.authorBuret, Andre G.-
dc.subjectConteúdo gastrointestinalpt_BR
dc.subjectSulfeto de hidrogêniopt_BR
dc.subject.otherlanguageGastrointestinal contentspt_BR
dc.subject.otherlanguageHydrogen sulfidept_BR
dc.description.abstractATB‐346 is a hydrogen sulfide (H2S)‐releasing anti‐inflammatory and analgesic drug. Animal studies demonstrated negligible gastrointestinal (GI) damage despite marked inhibition of COX activity and significant analgesic and anti‐inflammatory effects. In humans, ATB‐346 (250 mg once daily) was found to inhibit COX to the same extent as naproxen (550 mg twice daily). Two hundred forty‐four healthy volunteers completed a 2‐week, double‐blind study, taking either ATB‐346 (250 mg once daily) or naproxen (550 mg twice daily), with upper GI ulceration being examined endoscopically. Forty‐two per cent of the subjects taking naproxen developed at least one ulcer (≥3‐mm diameter), while only 3% of the subjects taking ATB‐346 developed at least one ulcer. The two drugs produced comparable and substantial (>94%) suppression of COX activity. Subjects in the naproxen group developed more ulcers per subject than ATB‐346‐treated subjects and a greater incidence of larger ulcers (≥5‐mm diameter). The incidence of dyspepsia, abdominal pain, gastro‐oesophageal reflux, and nausea was lower with ATB‐346 than with naproxen. Subjects treated with ATB‐346 had significantly higher plasma levels of H2S than those treated with naproxen. This Phase 2B study provides unequivocal evidence for a marked reduction of GI toxicity of the H2S‐releasing analgesic/anti‐inflammatory drug, ATB‐346, as compared to the conventional dose of naproxen that produced equivalent suppression of COXpt_BR
dc.relation.ispartofBritish journal of pharmacologypt_BR
dc.relation.ispartofabbreviationBr. j. pharmacol.pt_BR
dc.publisher.cityOxfordpt_BR
dc.publisher.countryReino Unidopt_BR
dc.publisherJohn Wiley & Sonspt_BR
dc.date.issued2020-
dc.date.monthofcirculationFeb.pt_BR
dc.language.isoengpt_BR
dc.description.volume177pt_BR
dc.description.issuenumber4pt_BR
dc.description.issuespecialThemed Issue: Hydrogen Sulfide in Biology & Medicine. Guest Editors: Andreas Papapetropoulos, John L. Wallace and Rui Wangpt_BR
dc.description.firstpage769pt_BR
dc.description.lastpage777pt_BR
dc.rightsFechadopt_BR
dc.sourceWOSpt_BR
dc.identifier.issn0007-1188pt_BR
dc.identifier.eissn1476-5381pt_BR
dc.identifier.doi10.1111/bph.14641pt_BR
dc.identifier.urlhttps://bpspubs.onlinelibrary.wiley.com/doi/full/10.1111/bph.14641pt_BR
dc.date.available2021-02-22T21:03:49Z-
dc.date.accessioned2021-02-22T21:03:49Z-
dc.description.provenanceSubmitted by Susilene Barbosa da Silva (susilene@unicamp.br) on 2021-02-22T21:03:49Z No. of bitstreams: 0en
dc.description.provenanceMade available in DSpace on 2021-02-22T21:03:49Z (GMT). No. of bitstreams: 0 Previous issue date: 2020en
dc.identifier.urihttp://repositorio.unicamp.br/jspui/handle/REPOSIP/356301-
dc.contributor.departmentDepartamento de Farmacologiapt_BR
dc.contributor.unidadeFaculdade de Ciências Médicaspt_BR
dc.subject.keywordPhase 2pt_BR
dc.identifier.source000513525100006pt_BR
dc.creator.orcid0000-0002-4346-7941pt_BR
dc.type.formArtigo de pesquisapt_BR
Appears in Collections:FCM - Artigos e Outros Documentos

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.